| Title |
Lenalidomide is safe and active in Waldenström macroglobulinemia
|
|---|---|
| Published in |
American Journal of Hematology, October 2015
|
| DOI | 10.1002/ajh.24175 |
| Pubmed ID | |
| Authors |
Guillemette Fouquet, Stéphanie Guidez, Marie-Odile Petillon, Chanaz Louni, Bella Ohyba, Malek Dib, Stéphanie Poulain, Charles Herbaux, Audrey Martin, Béatrice Thielemans, Pauline Brice, Sylvain Choquet, Jana Bakala, Claire Bories, Hélène Demarquette, Morgane Nudel, Olivier Tournilhac, Bertrand Arnulf, Steven LeGouill, Pierre Morel, Anne Banos, Lionel Karlin, Gilles Salles, Véronique Leblond, Xavier Leleu |
| Abstract |
Lenalidomide is manageable and effective in Multiple Myeloma, particularly in elderly patients. Surprisingly, the combination of lenalidomide with rituximab produced clinically significant anemia at 25mg/day for 21/28 days, the highest possible dose, in Waldenström's Macroglobulinemia (WM). We aimed to determine the maximum tolerated dose (MTD) of single agent lenalidomide and determine its impact on WM. RV-WM-0426 is a multicenter dose escalation open label phase 1/2 study of lenalidomide in relapsed/refractory WM (RRWM). Lenalidomide was given orally 21/28 days per cycle for one year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD. 17 RRWM patients were included. The MTD was established at 15 mg/day 21/28. By ITT analysis, the overall response rate was 29%. With a median follow-up of 36 months, median TTP was 16 months (95%CI 5.5-26), the 5-year OS was 91%. The most frequent AE ≥ grade 3 at 15mg were 14% anemia and 43% neutropenia. The MTD of lenalidomide is 15mg/day 21/28 days in RRWM. Lenalidomide is active in the treatment of RRWM and the safety profile appears manageable. Future studies may look into combinations of lenalidomide and continuous dosing. This article is protected by copyright. All rights reserved. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 50% |
| Members of the public | 1 | 25% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| United Kingdom | 1 | 2% |
| Unknown | 41 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 12% |
| Researcher | 4 | 9% |
| Other | 3 | 7% |
| Student > Bachelor | 3 | 7% |
| Lecturer | 2 | 5% |
| Other | 9 | 21% |
| Unknown | 17 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 28% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Agricultural and Biological Sciences | 2 | 5% |
| Immunology and Microbiology | 2 | 5% |
| Other | 4 | 9% |
| Unknown | 18 | 42% |